Effectiveness and Safety of Firmagon® in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma in Argentina

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01861236

Acronym

FAST AR

Enrollment

Registered

2013-05-23

Start date

2013-03-31

Completion date

2018-09-03

Last updated

2018-10-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Hormone Dependent Prostate Cancer

Brief summary

Prospective, observational study to collect and analyze data on patients with advanced hormone dependent prostate cancer treated with Firmagon® according to routine medical practice in Argentina

Interventions

DRUGFirmagon® (degarelix)

Monthly subcutaneous injections

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

MALE

Age

18 Years to 100 Years

Healthy volunteers

Inclusion criteria

* Advanced Prostate Cancer patients to be treated with Firmagon in the context of usual clinical practice * Written informed consent

Exclusion criteria

* Contraindications to Firmagon * Patients already on Firmagon therapy

Design outcomes

Primary

Measure	Time frame	Description
Progression-free survival (PFS) failure rate (with failure defined as either prostate-specific antigen (PSA) failure, introduction of additional therapy related to prostate cancer, or death)	During 3 years treatment	The PFS failure rate will be estimated with time to PFS failure as dependent and adjusting for disease stage at baseline, baseline PSA, baseline testosterone (if available) and baseline serum Alkaline Phosphatase (s-ALP, if available)

Countries

Argentina

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026